SERB Pharmaceuticals
SERB is a European specialty company focused on emergency and rescue medicines; in oncology it markets glucarpidase (Voraxaze) for toxic methotrexate levels and uridine triacetate (Vistogard) for fluorouracil overdose in Europe.
Overview
SERB acquired BTG's specialty pharmaceuticals business in 2021, adding Voraxaze (glucarpidase), CroFab and DigiFab, and distributes antidotes and rescue therapies used in oncology supportive care.
Scorecard
All companies- approved products +18
- modalities +6
- regions +2
- registry trials +11
Glucarpidase (Voraxaze) is a single emergency injection that chops up methotrexate in the blood when a patient's kidneys have failed to clear a high dose, preventing potentially fatal toxicity.
Telotristat ethyl (Xermelo) is a tablet that cuts the serotonin that neuroendocrine tumours pour out, easing the relentless diarrhoea of carcinoid syndrome when somatostatin analogue injections are not enough.
Uridine triacetate (Vistogard) is an oral antidote for fluorouracil or capecitabine overdose, or for dangerously early severe toxicity from these drugs, and must be started within four days of the chemotherapy.